Subscribe

TTY Biopharm Company Limited (4105.TWO)

TWD78.40 +0.80 (+1.03%)
TW TWO Healthcare Drug Manufacturers - Specialty & Generic
Address No.3-1, Park Street 11503
Taipei, TW
CEO Kuo-Chiang Chang
Website tty.com.tw
IPO 2007-12-31
ISIN TW0004105002

Explore sections of this company profile

Description

TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncology, Intensive Care, Healthcare, Export & CDMO, and an "Other" Business Unit. For anti-cancer and supportive therapies, the company markets a range of oncology medications under prominent brand names such as Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre. Addressing infectious diseases and influenza, TTY Biopharm supplies anti-infection drugs including Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax. Furthermore, the firm offers various healthcare-related pharmaceuticals designed for the digestive system, osteoporosis, and metabolic conditions, marketed under brands like Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin. Beyond pharmaceuticals, the company is also involved in distributing functional foods, conducting international trade (import/export), and engaging in investment ventures. Established in 1960, TTY Biopharm maintains its principal office in Taipei, Taiwan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD78.40 +0.80 (+1.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
845.2K
Beta
0.14
Float Shares
218.82M
Free Float %
88.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.13% +1.35% +1.07% -10.99% -4.92% -7.61% +0.00% +0.53% -7.04% -27.60% +517.21%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
78.40
DCF (Unlevered) 256.44 +227.1%
DCF (Levered) 252.18 +221.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.23
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +9.5% ★ Q1'26: +4.2% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +7.7% Q1'26: +13.4% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +15.5% Q1'26: +48.9% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +26.4% ★ Q1'26: +32.2% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +21.1% ★ Q1'26: +25.1% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +5.9% Q1'26: +4.5% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.72× ★ Q1'26: 0.63× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.06) × ERP
WACC = 94% × Ke + 6% × Kd (4.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 258.21 Current price: 78.40
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana.
Revenue
3.19B
est.
3.62B
est.
4.05B
est.
4.05B
est.
4.46B
est: 4.46B (0.0%)
4.22B
est: 4.24B (-0.5%)
4.54B
est: 4.49B (+1.1%)
5.06B
est: 5.07B (-0.1%)
5.51B
est: 5.45B (+1.1%)
5.89B
est: 5.85B (+0.7%)
6.45B
est: 6.49B (-0.6%)
7.05B
7.05B – 7.05B
+8.6% YoY
EBITDA
936.99M
est.
1.06B
est.
1.19B
est.
1.19B
est.
1.42B
est: 1.31B (+8.1%)
1.38B
est: 1.25B (+10.6%)
1.14B
est: 1.32B (-13.6%)
1.50B
est: 1.49B (+0.9%)
1.66B
est: 1.60B (+3.5%)
1.73B
est: 1.61B (+7.3%)
1.70B
est: 1.78B (-4.5%)
1.94B
1.94B – 1.94B
+8.6% YoY
EBIT
821.00M
est.
930.91M
est.
1.04B
est.
1.04B
est.
1.26B
est: 1.15B (+10.1%)
1.22B
est: 1.09B (+11.9%)
1.11B
est: 1.15B (-4.1%)
1.32B
est: 1.30B (+0.9%)
1.45B
est: 1.40B (+3.8%)
1.52B
est: 1.82B (-16.0%)
1.70B
est: 2.01B (-15.4%)
2.19B
2.19B – 2.19B
+8.6% YoY
Net Income
1.04B
est.
1.24B
est.
1.28B
est.
1.46B
est.
900.08M
est: 1.12B (-19.9%)
924.18M
est: 897.02M (+3.0%)
831.89M
est: 820.27M (+1.4%)
1.09B
est: 1.13B (-2.9%)
1.13B
est: 1.16B (-3.1%)
1.45B
est: 1.25B (+16.1%)
1.65B
est: 1.60B (+3.6%)
1.81B
1.81B – 1.81B
+13.1% YoY
SGA
952.68M
est.
1.08B
est.
1.21B
est.
1.21B
est.
1.33B
est: 1.33B (-0.4%)
1.39B
est: 1.27B (+9.6%)
1.32B
est: 1.34B (-1.1%)
1.44B
est: 1.51B (-5.0%)
1.60B
est: 1.63B (-1.5%)
1.75B
est: 1.36B (+28.5%)
—
est: 1.51B (-100.0%)
1.64B
1.64B – 1.64B
+8.6% YoY
EPS
4.17
est.
4.98
est.
5.16
est.
5.84
est.
3.62
est: 4.51 (-19.8%)
3.72
est: 3.60 (+3.3%)
3.35
est: 3.29 (+1.8%)
4.40
est: 4.53 (-2.8%)
4.54
est: 4.67 (-2.8%)
5.83
est: 4.73 (+23.3%)
6.27
est: 6.05 (+3.6%)
6.84
6.84 – 6.84
+13.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-05-07 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-05-06 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-05-05 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-05-04 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-30 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-29 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-28 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-27 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-24 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-23 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-22 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-21 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-20 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-17 A 4/5 5/5 5/5 5/5 2/5 3/5 3/5
2026-04-16 A 4/5 5/5 5/5 5/5 2/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.94B
OE per share TTM
7.77
Owner's Yield
9.64%
Maintenance CapEx ratio
14.71%
Maint CapEx / Avg PPE
46.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 55 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.04% 50.7K 0.42%
2 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.04% 28.0K 0.74%
3 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.04% 139.0K 0.72%
4 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.02% 82.7K 0.74%
5 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.02% 110.0K 0.55%
6 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.01% 1.69M 0.06%
7 Dimensional - Emerging Markets Value ETF DFEV 0.01% 226.0K 0.46%
8 Dimensional - Emerging Markets ex China Core Equity ETF DEXC 0.01% 26.7K 0.56%
9 Avantis Responsible Emerging Markets Equity ETF AVSE 0.01% 16.9K 0.33%
10 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.01% 626.9K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
3.04M
Shares Outstanding
248.65M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Allen Chu Head of Intensive Care Business Unit — male
Ching-Lan Hou General Manager — female
Jen-Yang Chang Chief Human Resource Officer — male
Kuo-Chiang Chang Chief Financial Officer — male
Shu-Fen Huang Chief Legal & Compliance Officer — female
Shu-Wen Wang Accounting Officer — female
Si-Yuan Yang Senior Vice President — female
Wei-Ying Yin Director of Public Affairs Department — —
Yung-Min Chiang Chief Auditor — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic